Cellectis SA company info

What does Cellectis SA do?
Cellectis (EPA:ALCLS), (NASDAQ:CLLS) is a biopharmaceutical company focused on developing immunotherapies based on gene-edited T-cells, using its pioneering TALEN technology and CRISPR-Cas9. The company is headquartered in Paris, France, and operates globally, aiming to harness the power of the immune system to target and eradicate cancers. Cellectis is also known for its innovative approach in the field of gene editing, endeavoring to create more effective and safer therapies for patients worldwide. Its project portfolio includes multiple pre-clinical and clinical trials, focusing primarily on CAR-T cell therapies, a groundbreaking approach in cancer treatment. Cellectis is driven by the objective to make accessible life-saving UCART product candidates to address unmet needs in the treatment of multiple aggressive cancers.
Cellectis SA company media
Company Snapshot

Is Cellectis SA a public or private company?


How many people does Cellectis SA employ?


What sector is Cellectis SA in?

pie chart
Health Care

Where is the head office for Cellectis SA?

location pin
Head Office
Paris, France

What year was Cellectis SA founded?

founded flag
Year Founded
What does Cellectis SA specialise in?
/Gene Editing /Cancer Therapies /Allogeneic CAR-T /Biopharmaceutical Products /Research Services /UCART Product Line

What are the products and/or services of Cellectis SA?

Overview of Cellectis SA offerings
UCART19, an engineered T-cell product targeting CD19-expressing malignancies.
ALLO-501, aimed at treating non-Hodgkin lymphoma through modified T-cells.
TALLEN, a gene-editing technology for precision genome modifications.
UCART123, developed for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.
UCART22, designed for B-cell acute lymphoblastic leukemia therapy.
BALLI-01 trial, assessing the safety and efficacy of UCART22 in B-ALL patients.

Who is in the executive team of Cellectis SA?

Cellectis SA leadership team
  • Dr. Andre  Choulika Ph.D.
    Dr. Andre Choulika Ph.D.
    Co-Founder, CEO & Director
  • Dr. David j. d. Sourdive Ph.D.
    Dr. David j. d. Sourdive Ph.D.
    Deputy CEO, Executive VP of CMC & Manufacturing and Director
  • Dr. Bing C. Wang M.B.A., Ph.D.
    Dr. Bing C. Wang M.B.A., Ph.D.
    Chief Financial Officer
  • Valerie  Cros
    Valerie Cros
    Principal Financial Officer & Principal Accounting Officer
  • Mr. Jean Charles Epinat
    Mr. Jean Charles Epinat
    Chief Technological Officer
  • Dr. Philippe  Duchateau Ph.D.
    Dr. Philippe Duchateau Ph.D.
    Chief Scientific Officer
  • Mr. Stephan  Reynier M.Sc.
    Mr. Stephan Reynier M.Sc.
    Chief Regulatory & Pharmaceutical Compliance Officer
  • Ms. Marie-Bleuenn  Terrier
    Ms. Marie-Bleuenn Terrier
    General Counsel & Secretary of the Board of Directors